Stock 688488 JIANGSU AIDEA PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jiangsu Aidea Pharmaceutical Co., Ltd.

Equities

688488

CNE1000041S6

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-07-09 pm EDT 		5-day change 1st Jan Change
9.85 CNY +3.58% Intraday chart for Jiangsu Aidea Pharmaceutical Co., Ltd. +2.39% -21.26%
May. 14 Jiangsu Aidea Pharmaceutical Co., Ltd. entered into an agreement to acquire 31.161% stake in Nanjing Nanda Pharmaceutical Co., Ltd. CI
Apr. 25 Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2023 2024 2025 2026
Capitalization 1 5,264 4,145 - -
Enterprise Value (EV) 1 5,264 4,145 4,145 4,145
P/E ratio -65.8 x - - -
Yield - - - -
Capitalization / Revenue - 8.15 x 4.96 x 3.84 x
EV / Revenue - 8.15 x 4.96 x 3.84 x
EV / EBITDA - -100 x 42.6 x 24.2 x
EV / FCF - - - -
FCF Yield - - - -
Price to Book - 3.86 x 3.91 x 3.69 x
Nbr of stocks (in thousands) 420,783 420,783 - -
Reference price 2 12.51 9.510 9.510 9.510
Announcement Date 2/23/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2023 2024 2025 2026
Net sales 1 - 508.6 834.9 1,080
EBITDA 1 - -41.44 97.38 171.5
EBIT 1 - -110.5 -17.82 64.84
Operating Margin - -21.73% -2.14% 6%
Earnings before Tax (EBT) - - - -
Net income -81.3 - - -
Net margin - - - -
EPS -0.1900 - - -
Free Cash Flow - - - -
FCF margin - - - -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 2/23/24 - - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2023 2024 2025 2026
Net Debt - - - -
Net Cash position - - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - - - -
ROE (net income / shareholders' equity) - -8.74% -1.4% 5.46%
ROA (Net income/ Total Assets) - - - -
Assets - - - -
Book Value Per Share 1 - 2.470 2.430 2.580
Cash Flow per Share 1 - 0.0100 -0.4500 0.2600
Capex - - - -
Capex / Sales - - - -
Announcement Date 2/23/24 - - -
1CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
9.85 CNY
Average target price
20.82 CNY
Spread / Average Target
+111.37%
Consensus

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
JIANGSU AIDEA PHARMACEUTICAL CO., LTD. Stock Jiangsu Aidea Pharmaceutical Co., Ltd.
-21.26% 550M
CSL LIMITED Stock CSL Limited
+3.84% 97.02B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+6.18% 40.94B
BIOGEN INC. Stock Biogen Inc.
-11.19% 33.35B
UCB Stock UCB
+83.78% 29.53B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.31% 15.76B
INCYTE CORPORATION Stock Incyte Corporation
-4.01% 13.65B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.70% 11.44B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+174.11% 10.08B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+6.14% 9.06B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 688488 Stock
  4. Financials Jiangsu Aidea Pharmaceutical Co., Ltd.